Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study

PURPOSE: Intravitreal vascular endothelial growth factor (VEGF) blockade is essential in many macular edema diseases treatment. However, intravitreal VEGF treatment has been reported to lead to deteriorated proteinuria and renal function. This study aimed to explore the relationship between renal ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Lin, Peng, Liying, Zhou, Yangzhong, Chen, Gang, Zhao, Bin, Li, Mingxi, Li, Xuemei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972674/
https://www.ncbi.nlm.nih.gov/pubmed/36865057
http://dx.doi.org/10.3389/fmed.2023.1100397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972674/
https://www.ncbi.nlm.nih.gov/pubmed/36865057
http://dx.doi.org/10.3389/fmed.2023.1100397

Ejemplares similares